论文部分内容阅读
目的探讨放射性125I粒子植入联合手术治疗脑恶性肿瘤的疗效。方法将脑恶性肿瘤患者200例随机分为试验组和对照组各100例。2组患者均给予降颅压等对症治疗和重症护理,试验组行常规大脑开颅恶性肿瘤切除术后给予放射性125I粒子植入放疗,而对照组仅给予常规大脑开颅恶性肿瘤切除术。术后密切随访,观察2组患者生存期、复发率、综合治疗有效率及不良反应发生率。结果试验组患者生存期为(69.82±12.76)周长于对照组的(45.61±10.35)周,复发率为14%(14/100)低于对照组的39%(39/100),治疗总有效率高于对照组,差异均有统计学意义(P<0.05)。试验组患者治疗后不良反应发生率与对照组相近,差异无统计学意义(P>0.05)。结论放射性125I粒子植入联合手术方式治疗脑恶性肿瘤具有较长的生存时间和较好的治疗效果,并未提高不良反应发生率。
Objective To investigate the efficacy of radioactive 125I seed implantation combined with surgical treatment of malignant brain tumors. Methods 200 patients with malignant brain tumors were randomly divided into experimental group and control group of 100 cases. Patients in both groups were given intracranial pressure and other symptomatic treatment and intensive care. In the experimental group, radioactive 125I seeds were implanted into radiotherapy after conventional brain craniotomy, whereas the control group was given only conventional craniotomy. After follow-up, the survival rate, recurrence rate, effective rate of comprehensive treatment and incidence of adverse reactions in two groups were observed. Results The survival time of the trial group was (69.82 ± 12.76) weeks compared with that of the control group (45.61 ± 10.35 weeks), the recurrence rate was 14% (14/100), which was lower than that of the control group (39/100) The efficiency is higher than the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the test group was similar to that in the control group, with no significant difference (P> 0.05). Conclusion Radioactive 125I seed implantation combined with surgical treatment of brain malignant tumor has a longer survival time and better therapeutic effect, did not increase the incidence of adverse reactions.